In Table 3, as compared to patients who did not suffer from END, those at risk of END had significantly elevated percentages of intraventricular hemorrhage (P < 0.01) and subarachnoid hemorrhage (P < 0.05) and displayed substantially raised Graeb scores (P < 0.01), NIHSS scores (P < 0.001), hematoma volume (P < 0.001), blood glucose levels (P < 0.001), and serum Nrf2 levels (P < 0.001). The gene discussed is NFE2L2; the disease is hematoma.